Skip to main content
Clinical Trials/ITMCTR2100004617
ITMCTR2100004617
Recruiting
Phase 1

A randomized double-blind controlled study on the efficacy and safety of Sangdanzhongfeng granule in the treatment of post-stroke spasticity

Hunan Academy of Chinese Medicine Affiliated Hospital0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Hunan Academy of Chinese Medicine Affiliated Hospital
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Hunan Academy of Chinese Medicine Affiliated Hospital

Eligibility Criteria

Inclusion Criteria

  • (1\) Western medicine diagnosis conforms to the diagnostic criteria of cerebral infarction;
  • (2\) TCM syndrome meets the criteria of yin deficiency and blood stasis syndrome;
  • (3\) Patients with limb hemiplegia and spasticity: the motor function evaluation criteria of hemiplegia in Brunnstrom 6 stage are above stage III, modified Ashworth score (MAS) \>\= 1, and \<\= grade 3;
  • (4\) Aged \>\= 18 and \<\= 80 years;
  • (5\) Conscious patients (GCS score \= 15\);
  • (6\) Duration ranges from 15 days to 90 days;
  • (7\) Patients who had not participated in other clinical trials in the last 3 months;
  • (8\) Patients or their family members agreed and signed informed consent.

Exclusion Criteria

  • (1\) Previous motor dysfunction, such as rheumatoid arthritis, limb surgery, joint deformities, multiple sclerosis, spinal cord injury, or neuromuscular lesions that affect limb activity;
  • (2\) Patients with a history of stroke and limb spasticity;
  • (3\) Patients with severe hepatorenal insufficiency (defined as ALT \> 2 times the normal upper limit or AST \> 2 times the normal upper limit). Severe renal insufficiency is defined as Cr \> 1\.5 times normal upper limit);
  • (4\) Complicated with other life\-threatening diseases such as severe heart, liver, kidney and endocrine diseases with an expected survival time of less than 3 months;
  • (5\) Inability to understand and/or follow up research procedures and/or follow\-up due to mental illness, cognitive or emotional disorders;
  • (6\) Allergic to Sangdanzhongfeng granule;
  • (7\) Pregnant or lactating women.
  • (8\) Ischemic stroke caused by other non\-arteriosclerosis, such as intracranial tumor, heart disease, blood disease, brain trauma and so on.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 4
A randomized double-blind controlled study for the evaluation of the clinical efficacy of the Tibetan medicine 'Fifteen Weisaierdou Pills'silt-type gallstones
ITMCTR2000003470Qinghai Jiumei Tibetan Medicine Pharmaceutical Co., Ltd.
Not yet recruiting
Phase 4
A randomized double-blind controlled study for the evaluation of the clinical efficacy of the Tibetan medicine 'Fifteen Weisaierdou Pills'
ITMCTR2000003469Qinghai Jiumei Tibetan Medicine Pharmaceutical Co., Ltd.
Not yet recruiting
Phase 1
A Randomized Double-blind Controlled Study on the Effect of Different Compatibility Ratios of Peony and Glycyrrhizae Herbs on the Clinical Efficacy of Jiedu Tongluo Shengjin GranulesSjogren syndrome
ITMCTR2000003741Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Recruiting
Not Applicable
A randomized, double-blind controlled study of the efficacy of infrared-whole body hyperthermia in patients with major depressioF32.1F32.2F33.1F33.2Moderate depressive episodeSevere depressive episode without psychotic symptomsRecurrent depressive disorder, current episode moderateRecurrent depressive disorder, current episode severe without psychotic symptoms
DRKS00015754Klinik für Psychiatrie und PsychotherapieCharité Campus Mitte82
Completed
Phase 2
Vitamin D supplementation for the treatment of Behcet's diseaseBehcet's disease.Behçet disease
IRCT201212216975N4Vice chancellor for research, Tabriz University of Medical Sciences50